## Shikhar Mehrotra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4986769/publications.pdf

Version: 2024-02-01

218677 243625 2,223 65 26 44 citations h-index g-index papers 67 67 67 4572 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Th17 Cells in Cancer: The Ultimate Identity Crisis. Frontiers in Immunology, 2014, 5, 276.	4.8	257
2	CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metabolism, 2018, 27, 85-100.e8.	16.2	197
3	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Frontiers in Immunology, 2018, 9, 1740.	4.8	155
4	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity, 2020, 52, 668-682.e7.	14.3	107
5	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Journal of Hematology and Oncology, 2017, 10, 82.	17.0	105
6	IL-2 and Beyond in Cancer Immunotherapy. Journal of Interferon and Cytokine Research, 2018, 38, 45-68.	1.2	83
7	ER stress-induced mediator C/EBP homologous protein thwarts effector TÂcell activity in tumors through T-bet repression. Nature Communications, 2019, 10, 1280.	12.8	83
8	A Quantitative Increase in Regulatory T Cells Controls Development of Vitiligo. Journal of Investigative Dermatology, 2014, 134, 1285-1294.	0.7	80
9	Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. Cell Reports, 2019, 28, 1879-1893.e7.	6.4	71
10	Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. Cancer Research, 2016, 76, 6006-6016.	0.9	56
11	Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice. Blood, 2019, 133, 266-279.	1.4	55
12	CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo. Journal of Investigative Dermatology, 2015, 135, 1574-1580.	0.7	50
13	Reducing CD73 Expression by $IL1\hat{l}^2$ -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. Cancer Research, 2014, 74, 6048-6059.	0.9	49
14	IL- $2R\hat{l}\pm$ mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Science Translational Medicine, 2015, 7, 311ra170.	12.4	49
15	A Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice. Journal of Immunology, 2012, 189, 1627-1638.	0.8	44
16	CD38: T Cell Immuno-Metabolic Modulator. Cells, 2020, 9, 1716.	4.1	43
17	Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clinical Cancer Research, 2019, 25, 1036-1049.	7.0	41
18	Replenishing Regulatory T Cells to HaltÂDepigmentation in Vitiligo. Journal of Investigative Dermatology Symposium Proceedings, 2017, 18, S38-S45.	0.8	38

#	Article	IF	CITATIONS
19	Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Cancer Research, 2016, 76, 6230-6240.	0.9	36
20	Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor TÂcell response. Cell Reports, 2021, 35, 109076.	6.4	35
21	Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions. Cancer Research, 2014, 74, 6036-6047.	0.9	34
22	The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue. Journal of Immunology, 2015, 194, 1737-1747.	0.8	34
23	Lack of <i>p53</i> Augments Antitumor Functions in Cytolytic T Cells. Cancer Research, 2016, 76, 5229-5240.	0.9	34
24	Antigen Specificity Enhances Disease Control by Tregs in Vitiligo. Frontiers in Immunology, 2020, 11, 581433.	4.8	34
25	Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget, 2017, 8, 30199-30216.	1.8	32
26	Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma. Free Radical Biology and Medicine, 2020, 160, 755-767.	2.9	30
27	S-Glutathionylation of estrogen receptor α affects dendritic cell function. Journal of Biological Chemistry, 2018, 293, 4366-4380.	3.4	29
28	Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. Journal of Biological Chemistry, 2019, 294, 9198-9212.	3.4	28
29	Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Scientific Reports, 2021, 11, 14232.	3.3	28
30	Identification of human CD4 $<$ sup>+ $<$ /sup> T cell populations with distinct antitumor activity. Science Advances, 2020, 6, .	10.3	27
31	Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent. Cancer Immunology Research, 2015, 3, 1364-1374.	3.4	26
32	Chapter 6 Oxidative Stress and Lymphocyte Persistence. Advances in Cancer Research, 2009, 102, 197-227.	5.0	22
33	Dietary Agents in Cancer Prevention: An Immunological Perspective ⟨sup⟩â€⟨ sup⟩. Photochemistry and Photobiology, 2012, 88, 1083-1098.	2.5	21
34	Carbon Monoxide Activates PERK-Regulated Autophagy to Induce Immunometabolic Reprogramming and Boost Antitumor T-cell Function. Cancer Research, 2022, 82, 1969-1990.	0.9	21
35	Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG Antibodies. Clinical Chemistry, 2020, 66, 1531-1537.	3.2	18
36	Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells. Cancer Research, 2022, 82, 2640-2655.	0.9	13

#	Article	IF	Citations
37	Changes in Class I and IIb HDACs by δ-Opioid in Chronic Rat Glaucoma Model. , 2020, 61, 4.		11
38	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. IScience, 2021, 24, 102489.	4.1	11
39	Impact of Mitochondrial Permeability on Endothelial Cell Immunogenicity in Transplantation. Transplantation, 2018, 102, 935-944.	1.0	10
40	Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control. Oncotarget, 2016, 7, 69371-69383.	1.8	10
41	Anti-oxidant capacity and anti-tumor T cell function: A direct correlation. Oncolmmunology, 2015, 4, e985942.	4.6	9
42	Interferon-Gamma (IFN- $\hat{l}^3$ )-Mediated Retinal Ganglion Cell Death in Human Tyrosinase T Cell Receptor Transgenic Mouse. PLoS ONE, 2014, 9, e89392.	2.5	8
43	Hematopoietic Stem Cells as a Novel Source of Dental Tissue Cells. Scientific Reports, 2018, 8, 8026.	3.3	8
44	Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo. Annals of Surgical Oncology, 2019, 26, 4782-4790.	1.5	8
45	Mesenchymal Stem Cells from Chronic Pancreatitis Patients Show Comparable Potency Compared to Cells from Healthy Donors. Stem Cells Translational Medicine, 2019, 8, 418-429.	3.3	8
46	New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. Cells, 2022, 11, 708.	4.1	8
47	Modulating donor mitochondrial fusion/fission delivers immunoprotective effects in cardiac transplantation. American Journal of Transplantation, 2022, 22, 386-401.	4.7	7
48	Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia, 2022, 36, 1907-1915.	7.2	7
49	Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Research, 2018, 78, 3067-3074.	0.9	6
50	Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma. Cancers, 2021, 13, 2696.	3.7	6
51	Histone Deacetylases Regulation by δ-Opioids in Human Optic Nerve Head Astrocytes. , 2020, 61, 17.		6
52	CD38-NAD+-Sirt1 axis in T cell immunotherapy. Aging, 2019, 11, 8743-8744.	3.1	6
53	Hematopoietic Stem Cell-Derived Functional Osteoblasts Exhibit Therapeutic Efficacy in a Murine Model of Osteogenesis Imperfecta. Stem Cells, 2021, 39, 1457-1477.	3.2	6
54	CD38: Modulating Histone Methyltransferase EZH2 Activity in SLE. Trends in Immunology, 2020, 41, 187-189.	6.8	5

#	Article	IF	CITATIONS
55	Eosinophils and melanoma: Implications for immunotherapy. Pigment Cell and Melanoma Research, 2022, 35, 192-202.	3.3	5
56	Reduction of Neuroinflammation by δ-Opioids Via STAT3-Dependent Pathway in Chronic Glaucoma Model. Frontiers in Pharmacology, 2021, 12, 601404.	3.5	4
57	Harnessing the IL-7/IL-7Rαaxis to improve tumor immunotherapy. Oncolmmunology, 2016, 5, e1122865.	4.6	3
58	Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255) Journal of Clinical Oncology, 2021, 39, TPS191-TPS191.	1.6	1
59	Enhance T Cell Immunotherapy By Targeting PIM-2 Kinase. Blood, 2016, 128, 815-815.	1.4	1
60	Dynamic Metabolism in Immune Response. Journal of Immunology Research and Therapy, 2016, 1, 37-48.	1.0	1
61	Macrophages as Stimulators of MART-1 <sub>27–35</sub> Epitope-Specific Human Cytolytic T Lymphocytes in vitro. Pathobiology, 2006, 73, 238-243.	3.8	0
62	PIM2 Kinase Regulates T-Cell Alloresponses and Graft-Versus-Host Disease in Mice. Blood, 2015, 126, 3074-3074.	1.4	0
63	A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma Journal of Clinical Oncology, 2016, 34, e14579-e14579.	1.6	0
64	Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2742-2742.	1.4	0
65	S1P/S1PR1 Signalis Required for Optimal T-Cell Pathogenicity to Induce Gvhd By RegulatingDrp1/mTOR Axis. Blood, 2021, 138, 643-643.	1.4	O